about
Whole-genome analysis of sporadic amyotrophic lateral sclerosisBehaviour, physiology and experience of pathological laughing and crying in amyotrophic lateral sclerosis.Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.Influenza-associated global amnesia and hippocampal imaging abnormality.Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis.Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions.Quantifying disease progression in amyotrophic lateral sclerosis.Pathogenicity of exonic indels in fused in sarcoma in amyotrophic lateral sclerosisAtaxin-2 repeat-length variation and neurodegenerationCognitive impairment, frontotemporal dementia, and the motor neuron diseases.Statistical motor unit number estimation: from theory to practice.C9ORF72 hexanucleotide repeat expansions in patients with ALS from the Coriell Cell Repository.An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditionsPrimary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional PopulationLength of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotypeFrontotemporal dementia in a Brazilian kindred with the c9orf72 mutation.TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's diseaseAmyotrophic lateral sclerosis from bench to bedside.Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis.Is IVIg therapy warranted in progressive lower motor neuron syndromes without conduction block?Clinical phenomenology and neuroimaging correlates in ALS-FTD.ALS Untangled No. 20: the Deanna protocol.Dysphagia in patients with frontotemporal lobar dementia.Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis.Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease - United States.Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters.Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.Cognitive and behavioral challenges in caring for patients with frontotemporal dementia and amyotrophic lateral sclerosis.Organ donation after cardiac death in amyotrophic lateral sclerosis.ALS treatment strikes out while trying for a homer: the topiramate trial.The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS.Quantitative ultrasound of denervated hand muscles.Cognitive-behavioral changes in amyotrophic lateral sclerosis: Screening prevalence and impact on patients and caregivers.Characterization of amyotrophic lateral sclerosis and frontotemporal dementia.Continuum of frontal lobe impairment in amyotrophic lateral sclerosis.The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.Japanese and American ALS patient preferences regarding TIV (tracheostomy with invasive ventilation): a cross-national survey.17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions.Progression and effect of cognitive-behavioral changes in patients with amyotrophic lateral sclerosis.
P50
Q24329076-E2B04BB6-767F-4F79-B900-807A15481AECQ30460222-E55C5E98-549F-418B-8F9B-9B6033D753C2Q30494108-7AF92B6C-115D-4FA5-B042-FC54F3E0E183Q30619235-FB8C2D13-134D-4E13-AA4B-ED1040E547CBQ30630835-20E96693-8495-40ED-AB4D-0D3373D7BFD2Q31105297-E201D8E6-CA49-4145-A833-1F8E0EC2A6B6Q34183099-90AB96A9-839C-4B63-BBA6-FED864FB0D97Q35008605-C51059BC-67FF-4639-97BC-F68B3A90A72BQ35089543-24A8C8D2-3541-46EE-9082-0DBB9040C026Q35119694-20DA80D2-E85A-4EAF-B769-8E6EFB13F176Q35165800-7B0E9B4F-14F7-42F0-ADCD-E65DB038FDDEQ35203385-C535A04C-40D6-4E70-89C0-C0A5D3EFE108Q36307091-17294BD7-987A-43E0-B5CD-ADD64AFDD8A8Q36551001-D78DCCD4-699C-411E-BD65-42E4E579C2C2Q36629768-FFF624B1-B569-4A1D-B368-EBAB53090FB4Q36742669-EEB6F110-27D0-4DA9-BCE7-FE39334E89D0Q36763619-DEC9B998-18D1-479C-9F77-4840BEEC08F3Q36952445-D8EECF17-6D57-4AAA-8486-7AE4865773B5Q37113869-163D793C-9DC3-4B04-A2E1-2893A881C68AQ37189268-40B33AD7-09BA-4CB4-9C73-A382F6D780B7Q37392566-37D1C09F-49B1-4592-BB33-658862BBA559Q37942499-6461F934-10B5-4A8B-B1A9-BC8DA3DC8FEDQ38103571-7C4AA1E9-3CE5-4687-ACA0-5F66BB32FD50Q38400642-2825510A-1389-4F09-9F95-9349CDDCDCEDQ39227306-2CAF6579-5F19-415C-BCF7-D175D5A2BCFCQ40171310-E5368A12-659E-478E-BCF4-B6A88C2ACE1FQ40437500-A8BB90B5-7AA6-40EA-ADE3-341CB98414C8Q41392222-40244DCC-E8F4-4B62-922E-9885D05EEFAFQ41977397-404B05FB-4E9C-4213-87DF-B75E9C14B5F6Q44540604-E2354028-0C4B-4990-BA6F-8482E9BF1B44Q44562241-20BA8EF2-4FDF-4B6A-8A9F-371D04064E8BQ44563255-C14497C1-78E8-4A75-89C4-335487806EFEQ46093112-3C42CA01-E449-42F7-A334-C131519BB920Q46101846-FD0A6B31-7580-4FBA-B67D-6D1122783250Q46234649-F530CE96-1A12-429F-BD43-064FF5928CDCQ46696678-16EDD5C7-9066-42B5-BD1D-C1248D0C1ADBQ46924395-2B9F2B71-AF76-4C6C-B044-E9BC76CD579FQ47654532-B0C27A0C-17C9-4546-A6B4-C7668D1B2929Q47945493-1F707ACB-4F3A-4883-B789-6A431A2C2FDEQ49438915-2C2C47A8-FCD1-4F82-8B1D-B103CA296191
P50
name
Catherine Lomen-Hoerth
@ast
Catherine Lomen-Hoerth
@en
Catherine Lomen-Hoerth
@nl
type
label
Catherine Lomen-Hoerth
@ast
Catherine Lomen-Hoerth
@en
Catherine Lomen-Hoerth
@nl
prefLabel
Catherine Lomen-Hoerth
@ast
Catherine Lomen-Hoerth
@en
Catherine Lomen-Hoerth
@nl
P214
P21
P214
P31
P735
P7859
viaf-311807831